Fig. 3
The pan-cancer prognostic value of ERO1α and PDI. Integrated Kaplan-Meier curves from the GEPIA2 database showing the prognostic effect of ERO1α (A) and PDI (B) expression with patients’ survival across 33 types of cancers. Prognostic analyses from the Kaplan-Meier Plotter database indicating the correlations of ERO1α (C) and PDI (D) with survival in specific cancers. ERO1α, endoplasmic reticulum oxidoreductase 1 alpha; PDIA1: protein disulfide isomerase A1; HR: hazard ratio. BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; ECA, Esophageal adenocarcinoma (EAC); ESCC, Esophageal squamous cell carcinoma; HNSC, Head and neck squamous cell carcinoma; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; OV, Ovarian serous cystadenocarcinoma; PDAC, Pancreatic ductal adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; READ, Rectum adenocarcinoma; SARC, Sarcoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma